Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.20), $0.19 better than the analyst estimate of ($1.39). Revenue for the quarter came in at $37.9 million versus the consensus estimate of $21.8 million.

• The non-GAAP net loss for the fourth quarter of 2017 was $115.1 million, or $1.20 per share on both a basic and diluted basis, as compared to a non-GAAP net loss of $92.3 million, or $1.08 per share on both a basic and diluted basis for the same period in the previous year.

2018 Financial Guidance

Alnylam expects that its cash, cash equivalents and fixed income marketable securities, restricted cash and restricted investments balance will be approximately $1.0 billion at December 31, 2018.

The Company expects its 2018 annual Non-GAAP R&D expenses to be in the range of $400 to $440 million and Non-GAAP selling, general and administrative (SG&A) expenses to be in the range of $280 to $320 million. Both Non-GAAP R&D and SG&A expenses exclude stock-based compensation expenses.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.